Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PsiOxus Will Seek $50m Series D Financing In H1 2018 To Fund Pipeline

Executive Summary

PsiOxus Therapeutics' CEO tells Scrip it will seek the fresh funding next year to progress its pipeline which aims to treat solid tumors through systemic delivery of oncolytic viruses.

You may also be interested in...



Boehringer Ingelheim Expands Oncolytic Virus Efforts With ViraTherapeutics Buy

Paying €210m for a company that only has preclinical programs may seem steep but BI is clearly impressed with the progress being made by its Austrian partner's lead candidate.

Merck & Co's Viralytics Buy Puts Oncolytic Viruses Back In Spotlight

The US major is spending $394m to get hold of Cavatak, an immunotherapy that it hopes will work well in combination with the anti-PD-1 blockbuster Keytruda.

Anjarium To Pioneer Next-Generation Non-Viral Gene Therapies

Emerging Company Profile: Switzerland-based Anjarium Biosciences AG has successfully raised $61m in a series A financing that will fund expansion of its novel proprietary platform and development of a nascent pipeline of non-viral gene therapies.   

Topics

Related Companies

UsernamePublicRestriction

Register

SC100073

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel